Video

Dr. Smith Discusses CD19 CAR T-Cell Therapy in B-ALL

Author(s):

Eric Smith, MD, PhD
Conference|European Hematology Association Congress

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) chimeric antigen receptor (CAR) T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL).

In a study of adult patients with relapsed/refractory B-ALL, investigators aimed to identify patients who would benefit from 19-28z CAR T-cell therapy, measured by durable long-term survival and reduced toxicities.

Results showed that the complete remission rate was 85% in this typically poor-prognosis setting.

Related Videos
John Seymour, MBBS, FRACP, PhD
Reid Merryman, MD
Partow Kebriaei, MD
Sonali M. Smith, MD
Sergio A. Giralt, MD
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lyudmila A. Bazhenova, MD, clinical professor, medicine, The University of California, San Diego (UCSD); medical oncologist, Moores Cancer Center, UCSD Health
Narjust Florez, MD, associate director, Cancer Care Equity Program, Dana-Farber Brigham Cancer Center; physician, Dana-Farber Cancer Institute; member, faculty, Harvard Medical School
Jonathan Wesley Riess, MD, MS, director, Thoracic Oncology, associate professor, medicine, Division of Hematology and Oncology, University of California, Davis Comprehensive Cancer Center
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Non-Hodgkin Lymphoma | Image Credit: © freshidea - stock.adobe.com
September 6th 2024

Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma

William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

Stefan K. Barta, MD, MS
September 6th 2024

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL

Meletios A. Dimopoulos, MD, professor, chairman, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine
September 6th 2024

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

Elias Jabbour, MD
September 6th 2024

Improved OS, Cost Effectiveness Are Necessary to Shift Later-Line TKIs to Frontline CML-CP

Stefan K. Barta, MD, MS
September 5th 2024

Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma